Washington Center for Bleeding Disorders at Bloodworks
Welcome,         Profile    Billing    Logout  
 3 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Konkle, Barbara A
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
Kouides, Peter A
NCT04055051: ATHN 11: Liver Transplantation Outcomes Study

Completed
N/A
86
US
American Thrombosis and Hemostasis Network, BioMarin Pharmaceutical
Hemophilia A and B, Liver Transplantation
12/22
12/22
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
Benton, Melody
NCT05695391: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting
3
19
US, RoW
Coagulation Factor VIIa (Recombinant)
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
06/25
07/25
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
NCT04724421: Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Available
N/A
US, RoW
Voxelotor, GBT440
Pfizer, Pfizer
Sickle Cell Disease
 
 
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Johnsen, Jill M
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
Ruuska, Sarah
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26

Download Options